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TO THE EDITOR
Basal cell carcinomas (BCCs) are the most
common cancers in the United States,
with an annual national incidence of ~2
million (Lomas et al., 2012). Although the
majority are localized to the skin and
cured by surgery, in rare cases, they can
progress to advanced and metastatic
tumors that result in severe morbidity
and death. BCCs are typically caused
by activating mutations in the sonic
hedgehog (HH) pathway, most
commonly through loss of the receptor
Patched1 (PTCH1) or activation of the
G-protein-coupled receptor Smoothened
(SMO; Epstein, 2008). Here, we report
the presence of Kinastrin (kinetochore-
localized astrin/SPAG5 binding protein
(KNSTRN)) mutations in BCC. KNSTRN
encodes a kinetochore-associated protein
that is an essential component of the
mitotic spindle and is required for faith-
ful chromosomal segregation during mito-
sis (Fang et al., 2009). It is expressed
in a broad range of tissues, including
skin, and its mutations have been
detected in both squamous-cell carci-
noma (SCC) and melanoma, leading to its
recent classiﬁcation as an oncogene (Lee
et al., 2014).
In order to elucidate the role of
KNSTRN in BCC, we interrogated 18Accepted article preview online 8 September 2015; published online 24 September 2015
Abbreviations: BCC, basal cell carcinoma; CNV, copy-number variation; COSMIC, Catalogue of Somatic
Mutations in Cancer; HH, sonic hedgehog pathway; KNSTRN, kinetochore-localized astrin/SPAG5
binding protein; PTCH1, patched 1; SCC, squamous-cell carcinoma; SMO, smoothened; TP53, tumor
protein 53
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advanced (inoperable and 43 cm in
size) and 30 early stage (o2 cm in size)
BCCs for mutations in KNSTRN (Stanford
Human Subjects panel approval and
subsequent written informed consent
was obtained from patients for tumor
sequencing (Protocol 18325)). Among
the advanced BCCs, whole-exome
sequencing revealed a mean of 1,428
somatic coding mutations per tumor,
equivalent to a nonsynonymous single-
nucleotide variant rate of 47.6 per Mb
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(range 5.5–125.6 per Mb), which is in the
low range of previous reports (Jayaraman
et al., 2014; Atwood et al., 2015). In
addition, all tumors had a mutational
proﬁle characteristic of exposure to UV
radiation, with C→T and A→T
transitions present in 68% of alterations
(SD 21%; Figure 1a). In all, 72% of
samples harbored mutations in PTCH1 or
SMO, consistent with the known patho-
genesis of BCC (Figure 1a and b;
Jayaraman et al., 2014; Atwood et al.,
2015).
Interestingly, 4 advanced BCCs (21%)
contained somatic mutations in KNSTRN
(Figure 1a and c). Three harbored the
KNSTRN p.S24F mutation, which has
previously been detected in both SCC
and melanoma (Lee et al., 2014). The
affected region of KNSTRN corresponds
to a UV-signature hotspot and involves
a C→T transition characteristic of
UV-induced mutagenesis. KNSTRN p.
S24F is predicted to be deleterious by
SIFT (Ng and Henikoff, 2001) and
Polyphen (Sunyaev et al., 2000), and
disrupts chromatid cohesion, increases
aneuploidy, and promotes Ras-driven
tumorigenesis in cell-based assays of
keratinocytes and in vivo mouse models
(Lee et al., 2014). The fourth advanced
BCC contained two KNSTRN mutations,
p.L9P and p.V12G, both of which were
predicted to be non-damaging by SIFT and
Polyphen; however, identical mutations
have been detected in liver, lung, and
gastric cancer, supporting a role in tumor-
igenesis. KNSTRN p.S24F, p.L9P, and
p.V12G have all been reported in the
Catalogue of Somatic Mutations in Cancer
(COSMIC) and are absent from dbSNP137
and ESP6500 (Figure 1c).
Compared with KNSTRN-wild-type
advanced BCCs, KNSTRN-mutated
advanced BCCs did not have a signiﬁ-
cant difference in average mutational
load or mean number of HH path-
way mutations, suggesting that HH
pathway-driven tumorigenesis is not
diminished or replaced by downstream
effects from mutant KNSTRN (Figure 1a
and d; Supplementary Figure 1 and
Supplementary Table 1 online). How-
ever, KNSTRN-mutated BCCs appeared
to have a higher rate of transitions
(85 vs. 64% transitions, P= 0.003), sup-
porting a role for KNSTRN in UV-
related mutagenesis (Figure 1d and
Supplementary Table 1 online).
Mutant KNSTRN has been functio-
nally shown to disrupt sister chromatid
cohesion and chromosome segregation
in keratinocytes; in KNSTRN-mutated
SCCs, this results in enhanced tumor
aneuploidy and increased genomic copy-
number aberrations (Lee et al., 2014). To
evaluate the functional relevance of
mutated KNSTRN in BCC, we expressed
wild-type- or S24F-mutated KNSTRN in a
murine BCC cell line (Figure 2a) and
assessed chromosome segregation during
mitosis. Interestingly, we found that
mutant KNSTRN expression disrupted
sister chromatid cohesion, as demon-
strated by a higher percentage of unpaired
sister chromatids in these cells (Figure 2b
and c). In conjunction with similar func-
tional studies in primary human keratino-
cytes and SCCs (Lee et al., 2014), these
data support a role for KNSTRN in
maintaining chromosomal stability. To
investigate large-scale genomic instability
and tumor aneuploidy in our advanced
BCCs, we employed a Bayesian-based
algorithm, BIC-seq, to detect the copy-
number variations (CNVs) in our samples
(Xi et al., 2011). PTCH1 deletions were
detected in 12% of tumors, consistent
with previous reports (Jayaraman et al.,
2014). There was a wide range in the
number of CNVs among both KNSTRN-
mutated and KNSTRN-wild-type samples
(Figure 1e), suggesting that advanced
BCCs have a large range of genetic
instability. On average, 1.9% (SD 2.0%)
Figure 1. The spectrum of basal cell carcinomas (BCCs) which harbor kinetochore-localized astrin/SPAG5 binding protein (KNSTRN) mutations. (a) The
percentage of transitions and transversions in 48 early stage and advanced BCCs. (b) Characteristics of the 48 BCCs. (c) Table of KNSTRN point mutations
identiﬁed in BCCs and Catalogue of Somatic Mutations in Cancer (COSMIC) database annotation. (d) Comparison of mean exonic mutations, sonic hedgehog
(HH)-pathway mutations, transitions, copy-number variations (CNVs), and SMO, TP53, and PTCH1 mutations in KNSTRN-mutated advanced BCCs and
KNSTRN-wild-type advanced BCCs. Error bars represent± SD (e) Scatterplot showing the total number of CNVs detected in each advanced BCC. (f) Percent of
samples with mutations in KNSTRN for normal skin (n=48), early stage BCCs (n=30) and advanced BCCs (n=18). *BCC48 lacked a paired normal sample, so
certain calculations could not be performed (see Supplementary Methods online).
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Figure 2. S24F kinetochore-localized astrin/SPAG5 binding protein (KNSTRN) disrupts sister chromatid
cohesion in a murine basal cell carcinoma (BCC) cell model. (a) Western blot analysis of ASZ001 cells
following transduction with empty vector (EV), wild-type Kinastrin (WT), or S24F mutant Kinastrin (S24F).
The level of enforced protein expression used to assess sister chromatid cohesion is shown. (b) Disrupted
sister chromatid cohesion in ASZ001 cells transduced to express EV, WT, or S24F Kinastrin. Arrowheads
mark unpaired chromatids. Scale bar = 5 μm. (c) Quantiﬁcation of unpaired chromatids. *P=0.04,
**P=0.005. ns, not signiﬁcant.
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of the exome was affected by CNVs
in KNSTRN-mutated tumors versus 1.4%
(SD 3.0%) in KNSTRN-wild-type tumors
(P=0.74). Although this was not statisti-
cally signiﬁcant, our ability to detect
differences may have been limited by a
small sample size.
In SCC, KNSTRN p.S24F is present in
19% of tumor precursors, suggesting
that it arises early in disease progression
(Lee et al., 2014). To determine whether
KNSTRN mutagenesis is an early event in
BCC development as well, we screened
30 early stage BCCs for KNSTRN
mutations. We identiﬁed a nonsynony-
mous KNSTRN mutation in only 1/30
(3%) early stage BCCs, suggesting that,
unlike in SCC, mutant KNSTRN in BCC
appears to be acquired later in disease
and is possibly a marker of aggressive
behavior (Figure 1c and f). The mutation,
pH284D, is absent from dbSNP137 and
ESP6500 and is predicted to be deleter-
ious by SIFT; however, it has not pre-
viously been reported in the COSMIC
database and is not predicted to be
damaging by Polyphen.
These ﬁndings are the ﬁrst to impli-
cate KNSTRN in BCC tumorigenesis.
Alongside recent data offering a role
for KNSTRN in SCC and melanoma,
our work supports the classiﬁcation
of KNSTRN as an oncogene and
an important contributor to the patho-
genesis of malignancies related to
UV-exposure. In both SCC and BCC,
mutant KNSTRN disrupts sister chroma-
tid cohesion and promotes genomic
instability in functional assays. How-
ever, unlike in SCC, KNSTRN muta-
tions in BCC appear to occur late in
disease progression and are preferen-
tially found in advanced tumors. Further
exploration of the role of KNSTRN in
skin cancer and genomic stability is
warranted.
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TO THE EDITOR
Declining estrogen levels in postmeno-
pausal women are related to delayed
wound healing. It is known that estro-
gen inﬂuences skin re-epithelialization
(Ashcroft et al., 1997) and may promote
skin wound healing via estrogen
receptor-β (ER-β Campbell et al.,
2010). However, the cellular and
subcellular mechanisms of estrogen’s
action on keratinocyte migration are
still poorly understood. Epithelial–
mesenchymal transition (EMT) is an
important process in which epithelial
cells lose their epithelial characteristics
and acquire mesenchymal traits. This
signiﬁcant phenotypic conversion leads
to the acquisition of motile behavior. In
the skin, EMT has been shown to have a
role in skin morphogenesis (Kong et al.,
2006), skin cancers (Shimokawa et al.,
2013; Wong et al., 2013; MagnoniAccepted article preview online 20 August 2015; published online 24 September 2015
Abbreviations: E2, 17β-estradiol; EMT, epithelial–mesenchymal transition; HaCaT, immortalized human
skin keratinocyte cell line; mRNA, messenger RNA; PHK, primary human keratinocyte
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